肿瘤负荷评分和临界可切除性标准作为晚期肝细胞癌生存的预测指标。 - Suppr

Suppr

超能文献

Tumor burden score and borderline resectability criteria as predictors of survival in advanced hepatocellular carcinoma.

作者信息

Dous Chahrazed

机构信息

Public Hospital of Theniet El Abed, Batna, Algeria.

出版信息

Hepatobiliary Surg Nutr. 2025 Aug 1;14(4):630-633. doi: 10.21037/hbsn-2025-312. Epub 2025 Jul 23.

DOI:10.21037/hbsn-2025-312

PMID:40893756

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12393124/

Abstract

摘要

相似文献

Tumor burden score and borderline resectability criteria as predictors of survival in advanced hepatocellular carcinoma.肿瘤负荷评分和临界可切除性标准作为晚期肝细胞癌生存的预测指标。

Hepatobiliary Surg Nutr. 2025 Aug 1;14(4):630-633. doi: 10.21037/hbsn-2025-312. Epub 2025 Jul 23.

International Validation and Refinement of Oncological Borderline Resectability Criteria for Hepatocellular Carcinoma Using Tumor Burden Score to Predict Survival.使用肿瘤负荷评分预测生存情况对肝细胞癌肿瘤学边界可切除性标准进行国际验证与优化

Ann Surg Open. 2025 Feb 26;6(1):e557. doi: 10.1097/AS9.0000000000000557. eCollection 2025 Mar.

Prognosis of Hepatectomy versus Systemic Chemotherapy Based on Oncological Resectability Criteria for Borderline Resectable Hepatocellular Carcinoma.基于临界可切除肝细胞癌肿瘤学可切除标准的肝切除术与全身化疗的预后

Liver Cancer. 2025 Jun 10. doi: 10.1159/000546830.

The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan.在日本，采用新建立的肿瘤可切除性标准，对接受阿替利珠单抗联合贝伐单抗治疗的不可切除肝细胞癌患者进行转化治疗的益处。

Hepatol Int. 2025 Feb 28. doi: 10.1007/s12072-025-10781-y.

Differential Prognostic Impact of Tumor Burden Score on Hepatocellular Carcinoma Patients with Variable Physical Performance Status.肿瘤负荷评分对不同身体状况的肝细胞癌患者的预后影响差异

Dig Dis Sci. 2025 Mar 28. doi: 10.1007/s10620-025-08971-7.

Vascular Invasion Within the Resectability Criteria Is a Prognostic Factor in Patients Treated With Atezolizumab and Bevacizumab.可切除性标准内的血管侵犯是接受阿替利珠单抗和贝伐单抗治疗患者的一个预后因素。

Liver Int. 2025 Aug;45(8):e70217. doi: 10.1111/liv.70217.

Survival impact and recurrence prediction using oncologic resectability classification in hepatocellular carcinoma following hepatic resection: a Japanese multi-center study.肝切除术后肝细胞癌的肿瘤可切除性分类对生存的影响及复发预测：一项日本多中心研究

Int J Clin Oncol. 2025 Jul 14. doi: 10.1007/s10147-025-02840-z.

Efficacy and safety of TACE combined with lenvatinib and PD-1 Inhibitor in intermediate-stage HCC exceeding the up-7 criteria: a retrospective cohort study.经动脉化疗栓塞术联合乐伐替尼和程序性死亡受体1抑制剂治疗超过up-7标准的中期肝细胞癌的疗效与安全性：一项回顾性队列研究

Front Immunol. 2025 Jun 12;16:1560750. doi: 10.3389/fimmu.2025.1560750. eCollection 2025.

Nomogram based on tumor burden score for prediction of prognosis of patients with hepatocellular carcinoma before hepatectomy.基于肿瘤负荷评分的列线图预测肝癌患者肝切除术前的预后。

Front Oncol. 2025 Jul 8;15:1578859. doi: 10.3389/fonc.2025.1578859. eCollection 2025.

Tumor burden score and alpha-fetoprotein level predict prognosis of patients with unresectable hepatocellular carcinoma treated with tyrosine kinase inhibitor and anti-PD-1 antibody.肿瘤负荷评分和甲胎蛋白水平可预测接受酪氨酸激酶抑制剂和抗程序性死亡蛋白1抗体治疗的不可切除肝细胞癌患者的预后。

ILIVER. 2024 Aug 8;3(3):100109. doi: 10.1016/j.iliver.2024.100109. eCollection 2024 Sep.

本文引用的文献

Ann Surg Open. 2025 Feb 26;6(1):e557. doi: 10.1097/AS9.0000000000000557. eCollection 2025 Mar.

Clinical Utility of the Novel Oncological Criteria of Resectability for Advanced Hepatocellular Carcinoma.晚期肝细胞癌新的可切除性肿瘤学标准的临床应用

Liver Cancer. 2024 May 16;13(6):601-609. doi: 10.1159/000539381. eCollection 2024 Dec.

Oncological Resectability Criteria for Hepatocellular Carcinoma in the Era of Novel Systemic Therapies: The Japan Liver Cancer Association and Japanese Society of Hepato-Biliary-Pancreatic Surgery Expert Consensus Statement 2023.新型全身治疗时代肝细胞癌的肿瘤可切除性标准：日本肝癌协会和日本肝胆胰外科学会2023年专家共识声明

Liver Cancer. 2024 Mar 29;13(6):0-10. doi: 10.1159/000538627. eCollection 2024 Dec.

Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape.2024年肝细胞癌的管理：不断演变的治疗格局中的多学科模式

Cancers (Basel). 2024 Feb 4;16(3):666. doi: 10.3390/cancers16030666.

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.BCLC 策略用于预后预测和治疗推荐：2022 年更新版。

J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19.

Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.肿瘤负担评分作为经动脉化疗栓塞治疗肝细胞癌患者的新预后标志物。

J Gastroenterol Hepatol. 2021 Nov;36(11):3196-3203. doi: 10.1111/jgh.15593. Epub 2021 Jul 5.

Using Hepatocellular Carcinoma Tumor Burden Score to Stratify Prognosis after Liver Transplantation.使用肝细胞癌肿瘤负担评分对肝移植后的预后进行分层

Cancers (Basel). 2020 Nov 14;12(11):3372. doi: 10.3390/cancers12113372.

Hepatocellular carcinoma tumour burden score to stratify prognosis after resection.肝细胞癌肿瘤负荷评分用于分层切除术后的预后。

Br J Surg. 2020 Jun;107(7):854-864. doi: 10.1002/bjs.11464. Epub 2020 Feb 14.

The Tumor Burden Score: A New "Metro-ticket" Prognostic Tool For Colorectal Liver Metastases Based on Tumor Size and Number of Tumors.肿瘤负荷评分：一种基于肿瘤大小和肿瘤数量的用于结直肠癌肝转移的新型“地铁票”预后工具。

Ann Surg. 2018 Jan;267(1):132-141. doi: 10.1097/SLA.0000000000002064.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验